

**REMARKS**

Support for the amendment to claim 2 can be found throughout the application including the Drawings and claims as filed originally. No new matter has been added.

Claims 1, 3-32, 34, 35, 44, 45, 48, 54, 56, and 62-69 have been cancelled. Claim 2 is pending. The right to file subsequent applications on cancelled subject matter is reserved.

Claim 2 was deemed allowable as indicated eg., on the outstanding office action summary.

Claims 1, 3-32, 34, 35, 44, 45, 48, 54, 56, and 62-69 were rejected on various grounds as set forth in the office action. Although Applicants respectfully disagree with each rejection, basis for them has been addressed by this submission. In particular, each of the claims has been cancelled with the exception of allowed claim 2.

Attached to this submission is a marked-up version of the changes made to the claims. The attached page is captioned "version with markings to show changes made".

In view thereof, early allowance of the instant application is requested.

Huganir et al.  
USSN 09/294,298  
Page -3-

Although it is not believed that any fee is needed to consider this paper, the USPTO is hereby authorized to charge our deposit account no. 04-1105 should any fee be found to be necessary.

Respectfully submitted,

Date: April 10, 2001



Robert L. Buchanan (Reg. No. 40,927)  
DIKE, BRONSTEIN, ROBERTS & CUSHMAN  
Intellectual Property Group  
EDWARDS & ANGELL, LLP  
130 Water Street  
Boston, MA 02109  
Tel: (617) 523-3400  
Fax: (617) 523-6440



VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the Claims:

Claims 1, 3-32, 34, 35, 44, 45, 48, 54, 56, and 62-69 have been cancelled.

Claim 2 has been amended as follows:

2. (Amended) . An isolated polynucleotide encoding a mammalian Synaptic GTPase Activating Protein (SYNGAP) ~~The polynucleotide of claim 1~~, wherein the polynucleotide comprises the sequence of any one of SEQ ID Nos. 1, 3, or 5.

#165505

RECEIVED

AUG 31 2001

OFFICE OF PETITIONS  
DEPUTY A/C PATENTS